© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
March 22, 2010
Cervarix (human papillomavirus bivalent [types 16 and 18] vaccine, recombinant) was approved by the FDA for use in girls and women aged 10 to 25 for the prevention of cervical precancers and cervical cancer associated with oncogenic human papillomaviras types 16 and 18.